Global Peripheral Neuropathy Treatment Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI05245160

Publication Date:

May 24, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Peripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical presentations, natural histories, and pathology.
The global Peripheral Neuropathy Treatment market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
The 鈥淧eripheral Neuropathy Treatment Industry Forecast鈥� looks at past sales and reviews total world Peripheral Neuropathy Treatment sales in 2023, providing a comprehensive analysis by region and market sector of projected Peripheral Neuropathy Treatment sales for 2024 through 2030. With Peripheral Neuropathy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peripheral Neuropathy Treatment industry.
This Insight Report provides a comprehensive analysis of the global Peripheral Neuropathy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peripheral Neuropathy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Peripheral Neuropathy Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peripheral Neuropathy Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peripheral Neuropathy Treatment.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Peripheral Neuropathy Treatment market by product type, application, key players and key regions and countries.
Segmentation by type
Calcium Channel 伪2-delta Ligands
Antidepressants
Opioids
Others
Segmentation by application
Platinum Agents
Taxanes
Vinca Alkaloids
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Eli Lilly
Johnson & Johnson
Novartis
Pfizer
Aptinyx
Regenacy Pharmaceuticals
TEVA Pharmaceutical Industries
Immune Pharmaceuticals

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peripheral Neuropathy Treatment Market Size 2019-2030
2.1.2 Peripheral Neuropathy Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Peripheral Neuropathy Treatment Segment by Type
2.2.1 Calcium Channel 伪2-delta Ligands
2.2.2 Antidepressants
2.2.3 Opioids
2.2.4 Others
2.3 Peripheral Neuropathy Treatment Market Size by Type
2.3.1 Peripheral Neuropathy Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Peripheral Neuropathy Treatment Market Size Market Share by Type (2019-2024)
2.4 Peripheral Neuropathy Treatment Segment by Application
2.4.1 Platinum Agents
2.4.2 Taxanes
2.4.3 Vinca Alkaloids
2.4.4 Others
2.5 Peripheral Neuropathy Treatment Market Size by Application
2.5.1 Peripheral Neuropathy Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Peripheral Neuropathy Treatment Market Size Market Share by Application (2019-2024)
3 Peripheral Neuropathy Treatment Market Size by Player
3.1 Peripheral Neuropathy Treatment Market Size Market Share by Players
3.1.1 Global Peripheral Neuropathy Treatment Revenue by Players (2019-2024)
3.1.2 Global Peripheral Neuropathy Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Peripheral Neuropathy Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Peripheral Neuropathy Treatment by Regions
4.1 Peripheral Neuropathy Treatment Market Size by Regions (2019-2024)
4.2 Americas Peripheral Neuropathy Treatment Market Size Growth (2019-2024)
4.3 APAC Peripheral Neuropathy Treatment Market Size Growth (2019-2024)
4.4 Europe Peripheral Neuropathy Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Peripheral Neuropathy Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Peripheral Neuropathy Treatment Market Size by Country (2019-2024)
5.2 Americas Peripheral Neuropathy Treatment Market Size by Type (2019-2024)
5.3 Americas Peripheral Neuropathy Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peripheral Neuropathy Treatment Market Size by Region (2019-2024)
6.2 APAC Peripheral Neuropathy Treatment Market Size by Type (2019-2024)
6.3 APAC Peripheral Neuropathy Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Peripheral Neuropathy Treatment by Country (2019-2024)
7.2 Europe Peripheral Neuropathy Treatment Market Size by Type (2019-2024)
7.3 Europe Peripheral Neuropathy Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peripheral Neuropathy Treatment by Region (2019-2024)
8.2 Middle East & Africa Peripheral Neuropathy Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Peripheral Neuropathy Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Peripheral Neuropathy Treatment Market Forecast
10.1 Global Peripheral Neuropathy Treatment Forecast by Regions (2025-2030)
10.1.1 Global Peripheral Neuropathy Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Peripheral Neuropathy Treatment Forecast
10.1.3 APAC Peripheral Neuropathy Treatment Forecast
10.1.4 Europe Peripheral Neuropathy Treatment Forecast
10.1.5 Middle East & Africa Peripheral Neuropathy Treatment Forecast
10.2 Americas Peripheral Neuropathy Treatment Forecast by Country (2025-2030)
10.2.1 United States Peripheral Neuropathy Treatment Market Forecast
10.2.2 Canada Peripheral Neuropathy Treatment Market Forecast
10.2.3 Mexico Peripheral Neuropathy Treatment Market Forecast
10.2.4 Brazil Peripheral Neuropathy Treatment Market Forecast
10.3 APAC Peripheral Neuropathy Treatment Forecast by Region (2025-2030)
10.3.1 China Peripheral Neuropathy Treatment Market Forecast
10.3.2 Japan Peripheral Neuropathy Treatment Market Forecast
10.3.3 Korea Peripheral Neuropathy Treatment Market Forecast
10.3.4 Southeast Asia Peripheral Neuropathy Treatment Market Forecast
10.3.5 India Peripheral Neuropathy Treatment Market Forecast
10.3.6 Australia Peripheral Neuropathy Treatment Market Forecast
10.4 Europe Peripheral Neuropathy Treatment Forecast by Country (2025-2030)
10.4.1 Germany Peripheral Neuropathy Treatment Market Forecast
10.4.2 France Peripheral Neuropathy Treatment Market Forecast
10.4.3 UK Peripheral Neuropathy Treatment Market Forecast
10.4.4 Italy Peripheral Neuropathy Treatment Market Forecast
10.4.5 Russia Peripheral Neuropathy Treatment Market Forecast
10.5 Middle East & Africa Peripheral Neuropathy Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Peripheral Neuropathy Treatment Market Forecast
10.5.2 South Africa Peripheral Neuropathy Treatment Market Forecast
10.5.3 Israel Peripheral Neuropathy Treatment Market Forecast
10.5.4 Turkey Peripheral Neuropathy Treatment Market Forecast
10.5.5 GCC Countries Peripheral Neuropathy Treatment Market Forecast
10.6 Global Peripheral Neuropathy Treatment Forecast by Type (2025-2030)
10.7 Global Peripheral Neuropathy Treatment Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Eli Lilly
11.1.1 Eli Lilly Company Information
11.1.2 Eli Lilly Peripheral Neuropathy Treatment Product Offered
11.1.3 Eli Lilly Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Eli Lilly Main Business Overview
11.1.5 Eli Lilly Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Peripheral Neuropathy Treatment Product Offered
11.2.3 Johnson & Johnson Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Peripheral Neuropathy Treatment Product Offered
11.3.3 Novartis Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Peripheral Neuropathy Treatment Product Offered
11.4.3 Pfizer Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Aptinyx
11.5.1 Aptinyx Company Information
11.5.2 Aptinyx Peripheral Neuropathy Treatment Product Offered
11.5.3 Aptinyx Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Aptinyx Main Business Overview
11.5.5 Aptinyx Latest Developments
11.6 Regenacy Pharmaceuticals
11.6.1 Regenacy Pharmaceuticals Company Information
11.6.2 Regenacy Pharmaceuticals Peripheral Neuropathy Treatment Product Offered
11.6.3 Regenacy Pharmaceuticals Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Regenacy Pharmaceuticals Main Business Overview
11.6.5 Regenacy Pharmaceuticals Latest Developments
11.7 TEVA Pharmaceutical Industries
11.7.1 TEVA Pharmaceutical Industries Company Information
11.7.2 TEVA Pharmaceutical Industries Peripheral Neuropathy Treatment Product Offered
11.7.3 TEVA Pharmaceutical Industries Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 TEVA Pharmaceutical Industries Main Business Overview
11.7.5 TEVA Pharmaceutical Industries Latest Developments
11.8 Immune Pharmaceuticals
11.8.1 Immune Pharmaceuticals Company Information
11.8.2 Immune Pharmaceuticals Peripheral Neuropathy Treatment Product Offered
11.8.3 Immune Pharmaceuticals Peripheral Neuropathy Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Immune Pharmaceuticals Main Business Overview
11.8.5 Immune Pharmaceuticals Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂